title: Patterns of infliximab use among Crohn's disease patients in a community setting.
abstract: BACKGROUND
  Information on infliximab use in a community setting is important to understand patterns of medication use and to anticipate and plan for costs associated with the drug. We sought to understand predictors of initiation and discontinuation of infliximab in the community-based setting of Kaiser Permanente, Northern California, which provides integrated care to its members.
  
  
  METHODS
  The cohort study was set during 1998-2006. Predictors of initiation were assessed among 494 Crohn's disease (CD) patients who initiated infliximab and 2470 CD patients who did not initiate infliximab (controls). Data were obtained through linkage of computerized clinical information and were analyzed using logistic regression and Cox survival analysis.
  
  
  RESULTS
  Infliximab infusions have increased rapidly since 2001, with no evidence of leveling off. Initiators were appreciably younger than controls (P < 0.001), but were similar to controls with respect to sex and race/ethnicity. The presence of at least 1 comorbidity was related to a modest increase in the risk of initiating (compared with none: 1 comorbidity, odds ratio [OR] = 1.52 with 95% confidence interval [CI] 1.16-2.00; 2 comorbidities, OR = 1.38 with CI 0.89-2.13). By 3 years after initiating, only 20% of patients remained on infliximab.
  
  
  CONCLUSIONS
  In a community-based setting infliximab use has steadily increased. Age and comorbidity are associated with initiation, but sex and race/ethnicity are not. More information is needed to determine why, in this community-based setting, a large number of patients on infliximab discontinued their treatment.(Inflamm Bowel Dis 2008).
authors.affiliation: Division of Research, Kaiser Permanente Northern California, Oakland, California 94612, USA.
authors.forename: Alice R
authors.initials: AR
authors.lastname: Pressman
authors.forename: Susan
authors.initials: S
authors.lastname: Hutfless
authors.forename: Fernando
authors.initials: F
authors.lastname: Velayos
authors.forename: Bruce
authors.initials: B
authors.lastname: Fireman
authors.forename: James D
authors.initials: JD
authors.lastname: Lewis
authors.forename: James
authors.initials: J
authors.lastname: Allison
authors.forename: Oren
authors.initials: O
authors.lastname: Abramson
authors.forename: Lisa J
authors.initials: LJ
authors.lastname: Herrinton
mesh_terms: D000293:Adolescent; D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D002140:California / Q000453:epidemiology; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D003424:Crohn Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D004363:Drug Utilization / Q000706:statistics & numerical data; D005260:Female; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D017063:Outcome Assessment, Health Care; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D000069285:Infliximab